TrialCompass TCL
Back to results
Phase 2RecruitingPriority 2 · High priorityNCT06630091

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

ClinicalTrials.gov

Plain-language summary

This Phase 2 trial is evaluating Golidocitinib, Cyclophosphamide, and other medications as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. It is available at 1 US location.

Who can join (key eligibility)

  • Age 18 Years or older
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Golidocitinib (DRUG): 150 mg once per day by PO | Cyclophosphamide (DRUG): 750 mg/m2 by IV | Doxorubicin (DRUG): 50 mg/m2 by IV | Vincristine (DRUG): 1.4 mg/m2 (max: 2 mg) by IV | Prednisone (DRUG): 100 mg by PO

Drugs / treatments
Golidocitinib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

NCT06630091

Phase: Phase 2 | Status: Recruiting | Priority: High

Plain-language summary

This Phase 2 trial is evaluating Golidocitinib, Cyclophosphamide, and other medications as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. It is available at 1 US location.

Who can join

  • Age 18 Years or older
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

What's being tested

Golidocitinib (DRUG): 150 mg once per day by PO | Cyclophosphamide (DRUG): 750 mg/m2 by IV | Doxorubicin (DRUG): 50 mg/m2 by IV | Vincristine (DRUG): 1.4 mg/m2 (max: 2 mg) by IV | Prednisone (DRUG): 100 mg by PO

Drugs / treatments: Golidocitinib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 30 patients

Primary endpoint: Safety and Adverse Events

Ages: 18 Years to —

Start date: 2025-02-21 | Est. completion: 2029-07-05

Locations

1 US sites · 1 total

Texas

Contact

Luis Malpica Castillo, MD | lemalpica@mdanderson.org | 713-563-8954

Sponsor: M.D. Anderson Cancer Center (OTHER)

Tags

All T-cell lymphomas · Newly diagnosed · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06630091

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.